TNF-α、CK20对结肠癌浸润、转移影响的研究及参芪扶正注射液的作用
|
摘要
结直肠癌是最常见的消化道肿瘤,据统计,自2002年至2007年,美国结直肠癌的死亡率占每年恶性肿瘤总死亡率的10%左右,连续5年排在第三位。在每年新发癌症患者中,结直肠癌同样以10%左右的发生率牢牢占据前三位。与此同时,结肠癌的发病年龄呈年轻化趋势,术后转移率、复发率逐年升高,已经引起疾病控制部门和临床医生的高度重视。
结肠癌的局部浸润和淋巴转移都在早期发生。因临床症状发生较晚、表现不典型及检查手段的局限性,使结肠癌的早期诊断愈加困难,客观上给结肠癌的浸润、转移提供了时间。恶性肿瘤的浸润、转移过程是由多因素参与的复杂过程,涉及细胞游走、定植、增殖、新生血管形成、免疫监视等多个方面,目前还没有确切的手段可以对这个过程进行监测和控制。结肠癌的局部浸润首先是肠壁内扩散,可以在2年左右的时间里环绕肠壁一周,还可以侵袭肠系膜甚至肠周围器官,直接与结肠癌的临床分期相关,对结肠癌的预后有重大的影响。淋巴转移则在结肠癌的转移过程中占主要地位,约占60%,在早期即有发生,不仅与结肠癌的临床分期有关,还可以指导术后进一步的抗肿瘤治疗,也是影响结肠癌患者预后的主要因素之一。因此,针对结肠癌浸润、淋巴转移的研究是相当重要和必要的。
目前针对结肠癌公认的治疗方案是以根治性手术切除为基础的肿瘤综合治疗,但是对于肿瘤部位相近、病理类型和分化程度相近、具有相同Dukes分期、同样施行了根治性手术和区域淋巴结清扫的患者,其预后和生存期限却有着显著的不同。这显然无法单纯用患者的年龄、身体状况和环境因素等来解释。因此,多数学者认为肿瘤的复发、转移是直接影响结肠癌患者预后的主要因素。如果可以对肿瘤细胞的浸润范围和能力进行严密的测定和监视,就可以有效地预防肿瘤局部复发,同样,如果能够对肿瘤的淋巴转移情况甚至淋巴微转移的情况进行监测和控制,则可以有效地预防和治疗术中、术后肿瘤转移的发生。
近年来恶性肿瘤微转移的研究成为热门课题,微转移主要是指一种肿瘤状态:使用常规的临床及病理诊断方法无法检测出来,但却保持了肿瘤细胞的生物学活性,具有增殖分化潜能,最终可以使肿瘤发生转移或复发,而且这种状态不能单纯用转移灶大小、部位等来定义。微转移涵盖微小的浸润、血行微转移、淋巴微转移和骨髓微转移等多个方面。在外科根治性手术已经进行的前提下,临床可见的肿瘤组织已经基本清除,常规病理学检查检测不到的微转移就成为影响肿瘤患者预后的重要因素。例如对于临床诊断为Dukes A、B期的结肠癌患者,因常规病理检查无淋巴结转移,在治疗规范中没有对这部分患者做出明确的术后辅助放疗、化疗的要求,如果忽略了可能已经发生的微转移的存在,就可能延误治疗,造成患者生存期限的差异。因此,微转移目前被认作是准确临床病理分期的必要补充,是指导采取何种治疗方式的关键。
细胞因子失衡被认为是恶性肿瘤生长、浸润、转移过程中必要的条件之一,近年来针对细胞因子与恶性肿瘤关系的研究逐渐增多。比较明确的有肿瘤坏死因子家族、白介素家族、生长因子家族和干扰素家族等。肿瘤坏死因子-α(tumor necrosis factor,TNF-α)是与恶性肿瘤关系密切的一种重要的细胞因子,主要由单核—巨噬细胞系统分泌,近年来的研究表明肿瘤细胞也可以产生,它不仅参与机体的免疫反应,还参与肿瘤的发生和发展过程,对肿瘤的进展和转移有着重要影响。
细胞角蛋白(cytokeratins, CKs)是一类多基因编码的非水溶性纤维性多肽,存在于上皮细胞的细胞质内,包括20多种亚型,其表达方式反映了上皮细胞分化的不同途径,其中部分亚型的单克隆抗体能识别特异表型的腺癌。癌细胞大多保留起源细胞的CKs类型,由此便可通过测定CKs来决定癌细胞的起源。如CK20具有严格组织特异性,局限于单层上皮及其起源的肿瘤细胞中,不仅在胃肠道、胰腺和胆管等原发部位的腺癌中表达,而且在转移它处后如肝、脊柱和脑转移性腺癌中仍保持其阳性表达特征,因此常作为上述肿瘤的标志物进行检测。
本次试验选取与恶性肿瘤关系密切的TNF-α和CK20两种指标,通过对结肠癌患者癌组织、癌旁组织、正常组织和淋巴结中TNF-αmRNA和CK20 mRNA表达情况的检测,试图揭示二者与结肠癌浸润和淋巴转移之间的关系,判断结肠癌的术后复发、亚临床转移发生的可能。提高对结肠癌患者预后的估计,指导结肠癌的临床治疗,并为研究淋巴微转移机制和利用TNF-α抑制结肠癌浸润和淋巴转移等提供一定的帮助。另外,使用Matrigel法研究参芪扶正注射液对结肠癌细胞系侵袭能力的影响、对TNF-αmRNA表达的影响等,为利用祖国传统医学治疗结肠癌提供了理论依据。
第一部分TNF-α、CK20在结肠癌浸润过程中表达的研究
目的:研究肿瘤坏死因子α(TNF-α)和细胞角蛋白20(CK20)在结肠癌患者组织中的表达和相关性及与肿瘤生物学行为的关系。方法:选取手术切除并经病理证实为结肠癌患者30例,采用RT-PCR法,检测结肠癌患者癌组织、癌旁组织、切缘组织中TNF-αmRNA和CK20 mRNA的表达情况。
结果:三种组织中TNF-αmRNA表达阳性率分别为70.0%、43.3%、20.0%,三者比较差异有统计学意义(P<0.01);CK20 mRNA表达阳性率分别为63.3%、33.3%、16.7%,差异有统计学意义(P<0.01),但在癌旁和切缘组织之间表达差异无统计学意义(P>0.05)。TNF-αmRNA和CK20 mRNA的表达之间具有良好的相关性。TNF-αmRNA和CK20 mRNA与结肠癌分化程度无关(P>0.05),但TNF-αmRNA与结肠癌Dukes分期、侵及肠壁范围密切相关(P<0.05)。
结论:TNF-αmRNA可以作为反映结肠癌的浸润能力的客观指标。
第二部分TNF-α、CK20在结肠癌淋巴微转移中表达的研究
目的:研究肿瘤坏死因子α(TNF-α)mRNA和细胞角蛋白20(CK20)mRNA在结肠癌患者淋巴结中的表达情况,探讨二者与结肠癌淋巴微转移的关系。
方法:选取手术切除并经病理证实的30例结肠癌患者,收集淋巴结共计398枚,采用连续切片和RT-PCR法,检测淋巴结中微转移灶的存在情况和TNF-αmRNA和CK20 mRNA的表达情况。
结果:连续切片结果显示,在常规病理无转移的淋巴结中有20.2%的淋巴结存在微转移,TNF-αmRNA和CK20 mRNA的表达与连续切片的检查结果基本吻合,三者之间具有良好的相关性。TNF-αmRNA和CK20 mRNA的表达随Dukes分期增加而增高,P<0.05。在转移阳性淋巴结中表达高于转移阴性淋巴结,P<0.01。
结论:TNF-αmRNA和CK20 mRNA均可以准确地反映结肠癌淋巴微转移的情况,TNF-α具有和CK20一样的反映结肠癌淋巴微转移情况的能力,可能在结肠癌淋巴微转移的过程中起重要作用。
第三部分参芪扶正注射液对结肠癌侵袭能力的影响
目的:研究参芪扶正注射液对结肠癌细胞系侵袭能力的作用及对TNF-αmRNA、CK20 mRNA表达的影响。
方法:用Matrigel法检测不同浓度的参芪扶正注射液对体外培养结肠癌细胞株Caco-2和LS-174T细胞侵袭能力的影响;用RT-PCR法检测不同参芪扶正注射液的浓度状态下结肠癌细胞株TNF-αmRNA、CK20 mRNA的表达情况。
结果:在不同浓度的参芪扶正注射液作用下,CK20 mRNA的表达情况在各组之间无明显差异,对照组TNF-αmRNA的表达明显高于用药组,低浓度组明显高于高浓度组。在浓度为10%时,两组细胞系的穿膜细胞数最低,各组间差异有统计学意义。
结论:参芪扶正注射液对结肠癌细胞表达TNF-αmRNA的能力有很大影响,不同浓度的参芪扶正注射液可以对结肠癌细胞的侵袭能力产生强弱不同的抑制作用,随着浓度的加大,TNF-αmRNA的表达逐渐减弱,抑制作用逐渐增强。
Issue one Expression of tumor necrosis factor-αand cytokeratin 20 the process of invasion of colon cancer
Objective: To investigate the expression and the relevance of tumor necrosis factor-α(TNF-α) mRNA and cytokeratin20(CK20) mRNA in the tissues of patients with colon cancer and the relation between the expression and the oncobiological behavior.
Methods: Surgically resected and pathologically confirmed 30 cases of colon cancer patients were internalized, RT-PCR technique was used to detect the expression of TNF-αmRNA and CK20 mRNA in the tumor, para-tumor and incisal margin tissues.
Resul: The positive rates of TNF-αmRNA expressions in the three groups were 70.0% and 43.3%, 20.0% respectively with a Statistical significant difference (P<0.01), and the positive rates of CK20 mRNA expression were 63.3%, 33.3% and 16.7% also with a Statistical significant difference (P<0.01), but there was no Statistical significant difference between the para-tumor and incisal margin groups (P>0.05). TNF-αmRNA and the CK20 mRNA expression were deeply correlated. TNF-αmRNA and CK20 mRNA was foreign to the differentiation of colon cancer (P>0.05), but TNF-αmRNA is closely related to colon cancer Dukes stages and the invasion extence in the intestinal wall (P<0.01).
Conclusion: TNF-αmRNA can be used to speculate the invasional capacity of colon cancer as an objective indicator.
Issue two Expression of TNF-αand CK20 in the lymphatic micro-metastasis in colon cancer
Objective: To investigate the expressions of TNF-αmRNA and CK20 mRNA in the lymph nodes of patients with colon cancer and to discuss their relations to lymphatic micro-metastasis of colon cancer.
Methods: A total of 398 lymph nodes were collected from surgically resected and pathologically confirmed 30 cases of colon cancer patients to be serially sliced and detected of lymphatic micro-metastasis as well as expression of TNF-αmRNA and CK20 mRNA through RT-PCR technique.
Results: 20.2 percent of non-lymphatic node metastases excepted by conventional pathologic examination has been found lymph node metastases by serial sections examination. The result of expression of TNF-αmRNA and CK20 mRNA were consistent on the whole to that of serial sections examination and the three presented a close correlation.the expression of TNF-αmRNA and CK20 mRNA were increased positively to the Dukes stages (P<0.05). The expression TNF-αmRNA and CK20 mRNA in positively transfered lymph nodes was superior to that of negative ones (P<0.01).
Conclusion: TNF-αmRNA and CK20 mRNA can accurately reflect lymphatic micro-metastases; uniform to CK20, TNF-αmRNA can also reflect the lymphatic micro-transfered capacity and probably plays an important role in the process of lymphatic micro-metastases of colon cancer.
Issue three Impact of Shenqi Fuzheng injection to capacity of invasion of colon cancer
Objective: To investigate the impact of Shenqi Fuzheng injection to the colon cancer cellular capacity of invasion and to expression of TNF-αmRNA, CK20 mRNA in colon cancer cell lines.
Methods: Colon cancer cell lines Caco-2 and LS-174T were cultured in vitro. After adding different concentrations of Shenqi Fuzheng injection, RT-PCR method was used to detect TNF-αmRNA, CK20 mRNA the expression of control group as well as the three Shenqi Fuzheng injection groups of different concentration. Impact of different concentration of Shenqi Fuzheng injection to the ability of cell migration of was detected by Matrigel.
Results: The expression of CK20 mRNA was no significant difference among the groups of different concentration of Shenqi Fuzheng injection. To the expression of TNF-αmRNA, the control group was significantly lower than that of drug groups and higher concentration group significantly lower than inferior concentration one (P<0.01).
Conclusion: Shenqi Fuzheng injection has great influence on the ability of colon cancer cells’expression of TNF-αmRNA. Different concentration of Shenqi Fuzheng injection can inhibit the abilities of movement or invasion of colon cancer cells in different extents, the inhibit ability is gradually strengthened and the TNF-αmRNA expression is gradually weaker with the concentration increased.
结肠癌的局部浸润和淋巴转移都在早期发生。因临床症状发生较晚、表现不典型及检查手段的局限性,使结肠癌的早期诊断愈加困难,客观上给结肠癌的浸润、转移提供了时间。恶性肿瘤的浸润、转移过程是由多因素参与的复杂过程,涉及细胞游走、定植、增殖、新生血管形成、免疫监视等多个方面,目前还没有确切的手段可以对这个过程进行监测和控制。结肠癌的局部浸润首先是肠壁内扩散,可以在2年左右的时间里环绕肠壁一周,还可以侵袭肠系膜甚至肠周围器官,直接与结肠癌的临床分期相关,对结肠癌的预后有重大的影响。淋巴转移则在结肠癌的转移过程中占主要地位,约占60%,在早期即有发生,不仅与结肠癌的临床分期有关,还可以指导术后进一步的抗肿瘤治疗,也是影响结肠癌患者预后的主要因素之一。因此,针对结肠癌浸润、淋巴转移的研究是相当重要和必要的。
目前针对结肠癌公认的治疗方案是以根治性手术切除为基础的肿瘤综合治疗,但是对于肿瘤部位相近、病理类型和分化程度相近、具有相同Dukes分期、同样施行了根治性手术和区域淋巴结清扫的患者,其预后和生存期限却有着显著的不同。这显然无法单纯用患者的年龄、身体状况和环境因素等来解释。因此,多数学者认为肿瘤的复发、转移是直接影响结肠癌患者预后的主要因素。如果可以对肿瘤细胞的浸润范围和能力进行严密的测定和监视,就可以有效地预防肿瘤局部复发,同样,如果能够对肿瘤的淋巴转移情况甚至淋巴微转移的情况进行监测和控制,则可以有效地预防和治疗术中、术后肿瘤转移的发生。
近年来恶性肿瘤微转移的研究成为热门课题,微转移主要是指一种肿瘤状态:使用常规的临床及病理诊断方法无法检测出来,但却保持了肿瘤细胞的生物学活性,具有增殖分化潜能,最终可以使肿瘤发生转移或复发,而且这种状态不能单纯用转移灶大小、部位等来定义。微转移涵盖微小的浸润、血行微转移、淋巴微转移和骨髓微转移等多个方面。在外科根治性手术已经进行的前提下,临床可见的肿瘤组织已经基本清除,常规病理学检查检测不到的微转移就成为影响肿瘤患者预后的重要因素。例如对于临床诊断为Dukes A、B期的结肠癌患者,因常规病理检查无淋巴结转移,在治疗规范中没有对这部分患者做出明确的术后辅助放疗、化疗的要求,如果忽略了可能已经发生的微转移的存在,就可能延误治疗,造成患者生存期限的差异。因此,微转移目前被认作是准确临床病理分期的必要补充,是指导采取何种治疗方式的关键。
细胞因子失衡被认为是恶性肿瘤生长、浸润、转移过程中必要的条件之一,近年来针对细胞因子与恶性肿瘤关系的研究逐渐增多。比较明确的有肿瘤坏死因子家族、白介素家族、生长因子家族和干扰素家族等。肿瘤坏死因子-α(tumor necrosis factor,TNF-α)是与恶性肿瘤关系密切的一种重要的细胞因子,主要由单核—巨噬细胞系统分泌,近年来的研究表明肿瘤细胞也可以产生,它不仅参与机体的免疫反应,还参与肿瘤的发生和发展过程,对肿瘤的进展和转移有着重要影响。
细胞角蛋白(cytokeratins, CKs)是一类多基因编码的非水溶性纤维性多肽,存在于上皮细胞的细胞质内,包括20多种亚型,其表达方式反映了上皮细胞分化的不同途径,其中部分亚型的单克隆抗体能识别特异表型的腺癌。癌细胞大多保留起源细胞的CKs类型,由此便可通过测定CKs来决定癌细胞的起源。如CK20具有严格组织特异性,局限于单层上皮及其起源的肿瘤细胞中,不仅在胃肠道、胰腺和胆管等原发部位的腺癌中表达,而且在转移它处后如肝、脊柱和脑转移性腺癌中仍保持其阳性表达特征,因此常作为上述肿瘤的标志物进行检测。
本次试验选取与恶性肿瘤关系密切的TNF-α和CK20两种指标,通过对结肠癌患者癌组织、癌旁组织、正常组织和淋巴结中TNF-αmRNA和CK20 mRNA表达情况的检测,试图揭示二者与结肠癌浸润和淋巴转移之间的关系,判断结肠癌的术后复发、亚临床转移发生的可能。提高对结肠癌患者预后的估计,指导结肠癌的临床治疗,并为研究淋巴微转移机制和利用TNF-α抑制结肠癌浸润和淋巴转移等提供一定的帮助。另外,使用Matrigel法研究参芪扶正注射液对结肠癌细胞系侵袭能力的影响、对TNF-αmRNA表达的影响等,为利用祖国传统医学治疗结肠癌提供了理论依据。
第一部分TNF-α、CK20在结肠癌浸润过程中表达的研究
目的:研究肿瘤坏死因子α(TNF-α)和细胞角蛋白20(CK20)在结肠癌患者组织中的表达和相关性及与肿瘤生物学行为的关系。方法:选取手术切除并经病理证实为结肠癌患者30例,采用RT-PCR法,检测结肠癌患者癌组织、癌旁组织、切缘组织中TNF-αmRNA和CK20 mRNA的表达情况。
结果:三种组织中TNF-αmRNA表达阳性率分别为70.0%、43.3%、20.0%,三者比较差异有统计学意义(P<0.01);CK20 mRNA表达阳性率分别为63.3%、33.3%、16.7%,差异有统计学意义(P<0.01),但在癌旁和切缘组织之间表达差异无统计学意义(P>0.05)。TNF-αmRNA和CK20 mRNA的表达之间具有良好的相关性。TNF-αmRNA和CK20 mRNA与结肠癌分化程度无关(P>0.05),但TNF-αmRNA与结肠癌Dukes分期、侵及肠壁范围密切相关(P<0.05)。
结论:TNF-αmRNA可以作为反映结肠癌的浸润能力的客观指标。
第二部分TNF-α、CK20在结肠癌淋巴微转移中表达的研究
目的:研究肿瘤坏死因子α(TNF-α)mRNA和细胞角蛋白20(CK20)mRNA在结肠癌患者淋巴结中的表达情况,探讨二者与结肠癌淋巴微转移的关系。
方法:选取手术切除并经病理证实的30例结肠癌患者,收集淋巴结共计398枚,采用连续切片和RT-PCR法,检测淋巴结中微转移灶的存在情况和TNF-αmRNA和CK20 mRNA的表达情况。
结果:连续切片结果显示,在常规病理无转移的淋巴结中有20.2%的淋巴结存在微转移,TNF-αmRNA和CK20 mRNA的表达与连续切片的检查结果基本吻合,三者之间具有良好的相关性。TNF-αmRNA和CK20 mRNA的表达随Dukes分期增加而增高,P<0.05。在转移阳性淋巴结中表达高于转移阴性淋巴结,P<0.01。
结论:TNF-αmRNA和CK20 mRNA均可以准确地反映结肠癌淋巴微转移的情况,TNF-α具有和CK20一样的反映结肠癌淋巴微转移情况的能力,可能在结肠癌淋巴微转移的过程中起重要作用。
第三部分参芪扶正注射液对结肠癌侵袭能力的影响
目的:研究参芪扶正注射液对结肠癌细胞系侵袭能力的作用及对TNF-αmRNA、CK20 mRNA表达的影响。
方法:用Matrigel法检测不同浓度的参芪扶正注射液对体外培养结肠癌细胞株Caco-2和LS-174T细胞侵袭能力的影响;用RT-PCR法检测不同参芪扶正注射液的浓度状态下结肠癌细胞株TNF-αmRNA、CK20 mRNA的表达情况。
结果:在不同浓度的参芪扶正注射液作用下,CK20 mRNA的表达情况在各组之间无明显差异,对照组TNF-αmRNA的表达明显高于用药组,低浓度组明显高于高浓度组。在浓度为10%时,两组细胞系的穿膜细胞数最低,各组间差异有统计学意义。
结论:参芪扶正注射液对结肠癌细胞表达TNF-αmRNA的能力有很大影响,不同浓度的参芪扶正注射液可以对结肠癌细胞的侵袭能力产生强弱不同的抑制作用,随着浓度的加大,TNF-αmRNA的表达逐渐减弱,抑制作用逐渐增强。
Issue one Expression of tumor necrosis factor-αand cytokeratin 20 the process of invasion of colon cancer
Objective: To investigate the expression and the relevance of tumor necrosis factor-α(TNF-α) mRNA and cytokeratin20(CK20) mRNA in the tissues of patients with colon cancer and the relation between the expression and the oncobiological behavior.
Methods: Surgically resected and pathologically confirmed 30 cases of colon cancer patients were internalized, RT-PCR technique was used to detect the expression of TNF-αmRNA and CK20 mRNA in the tumor, para-tumor and incisal margin tissues.
Resul: The positive rates of TNF-αmRNA expressions in the three groups were 70.0% and 43.3%, 20.0% respectively with a Statistical significant difference (P<0.01), and the positive rates of CK20 mRNA expression were 63.3%, 33.3% and 16.7% also with a Statistical significant difference (P<0.01), but there was no Statistical significant difference between the para-tumor and incisal margin groups (P>0.05). TNF-αmRNA and the CK20 mRNA expression were deeply correlated. TNF-αmRNA and CK20 mRNA was foreign to the differentiation of colon cancer (P>0.05), but TNF-αmRNA is closely related to colon cancer Dukes stages and the invasion extence in the intestinal wall (P<0.01).
Conclusion: TNF-αmRNA can be used to speculate the invasional capacity of colon cancer as an objective indicator.
Issue two Expression of TNF-αand CK20 in the lymphatic micro-metastasis in colon cancer
Objective: To investigate the expressions of TNF-αmRNA and CK20 mRNA in the lymph nodes of patients with colon cancer and to discuss their relations to lymphatic micro-metastasis of colon cancer.
Methods: A total of 398 lymph nodes were collected from surgically resected and pathologically confirmed 30 cases of colon cancer patients to be serially sliced and detected of lymphatic micro-metastasis as well as expression of TNF-αmRNA and CK20 mRNA through RT-PCR technique.
Results: 20.2 percent of non-lymphatic node metastases excepted by conventional pathologic examination has been found lymph node metastases by serial sections examination. The result of expression of TNF-αmRNA and CK20 mRNA were consistent on the whole to that of serial sections examination and the three presented a close correlation.the expression of TNF-αmRNA and CK20 mRNA were increased positively to the Dukes stages (P<0.05). The expression TNF-αmRNA and CK20 mRNA in positively transfered lymph nodes was superior to that of negative ones (P<0.01).
Conclusion: TNF-αmRNA and CK20 mRNA can accurately reflect lymphatic micro-metastases; uniform to CK20, TNF-αmRNA can also reflect the lymphatic micro-transfered capacity and probably plays an important role in the process of lymphatic micro-metastases of colon cancer.
Issue three Impact of Shenqi Fuzheng injection to capacity of invasion of colon cancer
Objective: To investigate the impact of Shenqi Fuzheng injection to the colon cancer cellular capacity of invasion and to expression of TNF-αmRNA, CK20 mRNA in colon cancer cell lines.
Methods: Colon cancer cell lines Caco-2 and LS-174T were cultured in vitro. After adding different concentrations of Shenqi Fuzheng injection, RT-PCR method was used to detect TNF-αmRNA, CK20 mRNA the expression of control group as well as the three Shenqi Fuzheng injection groups of different concentration. Impact of different concentration of Shenqi Fuzheng injection to the ability of cell migration of was detected by Matrigel.
Results: The expression of CK20 mRNA was no significant difference among the groups of different concentration of Shenqi Fuzheng injection. To the expression of TNF-αmRNA, the control group was significantly lower than that of drug groups and higher concentration group significantly lower than inferior concentration one (P<0.01).
Conclusion: Shenqi Fuzheng injection has great influence on the ability of colon cancer cells’expression of TNF-αmRNA. Different concentration of Shenqi Fuzheng injection can inhibit the abilities of movement or invasion of colon cancer cells in different extents, the inhibit ability is gradually strengthened and the TNF-αmRNA expression is gradually weaker with the concentration increased.
引文
1. Schmitt-Grohe S, Stuber F, Book M, et al. TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis [J]. Lung, 2006, 184(2): 99-104.
2. Osaka H, Yashiro M, Sawada T, et al. Is a lymph node detected by the dye-guided method a true sentinel node in gastric cancer [J]? Clin Cancer Res, 2004, 10(20): 6912-6918.
3.黄洁夫主编.腹部外科学[M],第一版.北京:人民卫生出版社, 2001, 1025-1030.
4. Hohmann HP, Remy R, Brockhaus M, et al. Two different cell types have different major receptors for humam tumor necrosis factor (TNF) [J]. J Biol Chem, 1989, 264 (25): 14927-14934.
5. Schultz RM, Altom MG. Protective activity of recombinant murine tumor necrosis factor-alpha and interferon-gamma against experimental murine lung carcinoma metastases [J]. J Interferon Res, 1990, 10(2): 229-236.
6. Paul NL, Ruddle NH. Lymph toxin. Annu Rev Immunol, 1988, 6(3): 407-438.
7.巴德年主编.当代免疫学技术与应用[M],第一版.北京:北京医科大学,中国协和医科大学出版联社, 1998, 52-54.
8. Van OX, Vandenabeele P, Everaerdt B, et al. Human TNF mutants with selective activity on the p55 receptor [J]. Nature, 1993, 361(6409): 266-299.
9. Janicke R, Mannel DN. Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis [J]. J Immunol, 1990, 144(3): 1144- 1149.
10. Occleston NL, Walker C. Production of multiple growth factors by a human non-small cell lung carcinoma cell line [J]. Cancer Lett, 1993, 71 (1-3): 203-210.
11.刘宇,贾友鹏,巩鹏,等.胆管癌中肿瘤坏死因子α及肿瘤坏死因子受体Ⅰ表达情况的研究[J].中国医师进修杂志, 2006, 29 (5): 33-36.
12. Volland S, Amtmann E, Sauer G. TNF accelerates the S-phase of the cell cycle in tumor cells [J]. Int J Cancer, 1994, 56(5): 698-705.
13. Utaisincharoen P, Ubol S, Tangthawornchaikul N, et al. Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RⅠinduces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines [J]. Clin Exp Immunol, 1999, 116(1): 41-47.
14. Chinnaiyan AM, Dixit VM. Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis [J]. Semin Immunol, 1997, 9(1): 69-76.
15. Chambers WM, Khan U, Gagliano A, et al. Tumour morphology as a predictor of outcome after local excision of rectal cancer [J]. Br J Surg, 2004, 91(4): 457-459.
16. Tominaga K, Nakanishi Y, Nimura S, et al. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma [J]. Dis Colon Rectum, 2005, 48(1): 92-100.
17. Yamamoto S, Watanabe M, Hasegawa H, et a1. The risk of lymph node metastasis in T1 colorectal carcinoma [J]. Hepatogastroenterology. 2004, 51(58): 998-1000.
18. Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study [J]. J Gastroenterol. 2004, 39(6): 534-543.
19. Moll R, Zimbelmann R, Goldschmidt MD, et al. The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas [J] . Differentiation , 1993 , 53(2): 75-93.
20.朱正,刘青,赵勇,等.恶性上皮性肿瘤中CK20的表达及其临床意义[J].临床与实验病理学杂志, 2004, 20(3): 332.
21. Funaki NO, Tanaka J, Itami A, et al. Detection of colorectal carcinoma cells in circulating peripheral blood by reverse transcription-polymerase chain reaction targeting cytokeratin-20 Mrna [J]. Life Sci, 1997, 60(9): 634-652.
1.黄洁夫主编.腹部外科学[M],第一版.北京:人民卫生出版社, 2001, 1025-1030.
2. Ovaska J, Jarvinen H, Kujari H, et al. Follow-up of patients operated on for colorectal carcinoma [J]. Am J Surg, 1990, 159(6): 593-596.
3. Kune GA, Kune S, Field B, et al. Survival in patients with large-bowel cancer [J]. Dis Colon Rectum, 1990, 33(11): 938-946.
4. Dean GT, Parks TG, Rowlands BJ, et al. Prognostic factors in colorectal cancer [J]. Lancet, 1995, 345(8960): 1257-1259.
5. Feezor RJ, Copeland EM, Hochwald SN, et al. Significance of micrometastases in colorectal cancer[J]. Ann Surg Oncol, 2002, 9(10): 944-953.
6. Hayashi N, Arakawa H, Nagase H, et al. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method [J]. cancer Res, 1994, 54(14): 3853-3856.
7. Hermanek P, Hutter RV, Sobin LH, et al. International union against cancer. Classification of isolated tumor cells and micrometastasis [J]. Cancer, 1999, 86(12): 2668-2673.
8. Ross GL, Shoaib T, Soutar DS, et al. The first international conference sentinel node biopsyin mucosal head and neck cancer and adoption of a multicenter trialprotocol [J]. Ann Surg Oncol, 2002, 9(4): 406-410.
9. Sedmak DD, Meineke TA, Knechtges DS. Detection of metastatic breast carcinoma with monoclonal antibodies to cytokeratins [J]. Arch Pathol Lab Med, 1989, 113(7): 786-789.
10. Leong AS. The prognostic dilemma of nodal micrometastases in breast carcinoma [J]. Gan To Kagaku Ryoho, 2000, 27(2): 315-320.
11. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review[J]. J Surg Oncol, 1998, 67(3): 194-202.
12. Davidson BR, Sams VR, Styles J, et al. Detection of occult nodal metastases in patients with colorectal carcinoma [J]. Cancer, 1990, 65(4): 967-970.
13. Mori M, Mimori K, Inoue H, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase reaction [J]. Cancer Res, 1995, 55(15): 3417-3420.
14. Gerhard M, Juhl H, Kalthoff H, et al. Specific detection of carcinoembryonicantigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction [J]. J Clin Oncol, 1994, 12(4): 725-729.
15. Moll R, Lowe A, Franke WW. Cytokeratin 20 in human carcinomas: a new histodiagnostic marker detected by monoclonal antibodies [J]. AM J Pathol, 1992, 140(2): 427-447.
16. Dorudi S, Kinrade E, Marshall NC, et al. Genetic detection of lymph node micrometastases in patients with colorectal cancer [J]. Br J Surg, 1998, 85(1): 98-100.
17.朱正,刘青,赵勇,等.恶性上皮性肿瘤中CK20的表达及其临床意义[J].临床与实验病理学杂志, 2004, 20(3): 332.
18. Moll I, Kuhn C, Moll R. Cytokeratin 20 is a general marker of cutaneous Merkel cells while certain neuronal proteins are absent [J]. J Invest Dermatol, 1995, 104(6): 910-915.
19.刘宇,贾友鹏,巩鹏,等.胆管癌中肿瘤坏死因子α及肿瘤坏死因子受体Ⅰ表达情况的研究[J].中国医师进修杂志, 2006, 29(5): 33-36.
20. Volland S, Amtmann E, Sauer G. TNF accelerates the S-phase of the cell cycle in tumor cells [J]. Int J Cancer, 1994, 56(5): 698-705.
21. Denis MG, Lipart C, Leborgne J, et al. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients [J]. Int J Cancer, 1997, 74(5): 540-544.
22. Noura S, Yamamoto H, Ohnishi T, et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry [J]. J Clin Oncol, 2002, 20(20): 4232-4241.
23. Takayama O, Yamamoto H, Ikeda K, et al. Application of RT-PCR to clinical diagnosis of micrometastasis of colorectal cancer: A translational research study [J]. Int J Oncol, 2004, 25(3): 597-604.
1. Somlyo AV, Bradshaw D, Ramos S,et al. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells [J].Biochem Biophys Res Common, 2000, 269(3): 652-659.
2. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth [J]. Cancer Res, 1996, 56(4): 921-924.
3. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis [J]. Cancer Chemother Pharmacol, 1999, 43 Suppl: S42-51.
4. Debruyne P, Vermeulen S, Mareel M. The role of the E-cadherin/catenin complex in gastrointestinal cancer [J]. Acta Gastroenterol Belg, 1999, 64(4): 393-402.
5. Patel AS, Schechter GL, Wasilenko WJ, et al. Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro [J]. Oncogene, 1998, 16(25): 3227-3332.
6. Tachado SD, Mayhew MW, Wescott GG, et al. Regulation of tumor invasion and metastasis in protein kinase C epsilon-transformed NIH3T3 fibroblasts [J]. J Cell Biochem, 2002, 85(4): 785-797.
7. Tullberg K, Haidvogl H, Obrist R, et al. Selection of highly malignant tumour cells using reconstituted basement membrane matrix [J]. Invasion Metastasis, 1989, 9(1): 15-26.
8.杨子昂,靳大勇,吴国象,等.基质金属蛋白酶及其抑制因子检测结直肠癌术后肝转移的研究[J].中国实用外科杂志, 2004, 24(3): 171-172.
9.吴莉,姜彬,杨洁,等.参芪扶正注射液联合化疗治疗晚期非小细胞肺癌30例[J].中国中西医结合杂志, 2004, 24(6): 567-568.
10.耿维风,陈敏.参芪扶正注射液临床初步观察[J].中国医院药学杂志, 2003, 23(9): 554-556.
11.王晓华,郑颖.现代简明中医中药[M].南京:江苏科技出版社, 2005, 281-284.
12.姚志华,张明智.中药抗恶性肿瘤研究进展[J].现代肿瘤医学, 2006, 14(4): 503-505.
13.付玉兰,李辉贤,雷成阳,等.参芪扶正注射液配合卵巢癌术后化疗临床观察[J].现代肿瘤医学, 2005, 13(1): 110-111.
14. Fridkis-Hareli M, Reinherz EL. New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination[J].Med Immuno, 2004, 3(1): 2.
15. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity [J]. Nat Rev Microbiol, 2005, 3(1): 59-69.
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 [J]. CA Cancer J Clin, 2007, 57(1): 43-66.
2.吴阶平,裘法祖主编.黄家驷外科学[M],第六版.北京:人民卫生出版社, 1999,1134-1135.
3.黄洁夫主编.腹部外科学[M],第一版.北京:人民卫生出版社, 2001, 1025-1030.
4. Wheeler JM, Dodds E, Warren BF, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade [J]. Dis Colon Rectum, 2004, 47(12): 2025-2031.
5. Papadopoulou-Zekeridou P, Alexandridis E, Delithanasis I, et al. Adjuvant chemotherapy in colorectal cancer [J]. Tech Coloproctol, 2004, 8 Suppl 1: 149-151.
6.汤钊猷主编.现代肿瘤学[M],第二版.上海:上海医科大学出版社, 2002, 521-552.
7. Spiliotis J, Datsis A. The surgical approach to locally recurrent rectal cancer [J]. Tech Coloproctol, 2004, 8 Suppl 1: s33-35.
8. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review [J]. J Surg Oncol, 1998, 67(3): 194-202.
9.朱世能,陆世伦主编.肿瘤基础理论[M],第二版.上海:上海医科大学出版社, 2000, 264-279.
10. Chambers WM, Khan U, Gagliano A, et al. Tumour morphology as a predictor of outcome after local excision of rectal cancer [J]. Br J Surg, 2004, 4(2): 457-459.
11. Tominaga K, Nakanishi Y, Nimura S, et al. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma [J]. Dis Colon Rectum, 2005 , 48(1): 92-100.
12. Yamamoto S, Watanabe M, Hasegawa H, et a1.The risk of lymph node metastasis in T1 colorectal carcinoma [J]. Hepatogastroenterology, 2004, 51(58): 998-1000.
13. Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study [J]. J Gastroenterol, 2004, 39(6): 534-543.
14. Scheidbach H, Lippert H, Kockerling F. Laparoscopic colorectal resection with curative intent. Own results and review of the literature [J]. Minerva Chir, 2003, 58(4): 439-446.
15. Shirouzu K, Ogata Y, Araki Y. Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer [J]. Dis Colon Rectum, 2004, 47(9): 1442-1447.
16. Ueno H, Hase K, Mochizuki H. Criteria for extramural perineural invasion as a prognostic factor in rectal cancer [J]. Br J Surg, 2001, 88(7): 994-1000.
17.龚丽明,程若川,李恩全.大肠癌微转移检测的现状及展望[J].大肠肛门病外科杂志, 2003, 9(3): 137-142.
18. Braat AE, Oosterhuis JW, Moll FC, et al. Successful sentinel node identification in colon carcinoma using Patent Blue V [J]. Eur J Surg Oncol, 2004, 30(6): 633-637.
19. Futamura M, Takagi Y, Koumura H, et al. Spread of colorectal cancer micrometastasis in reginal lymph node by reverse transcriptase polymerise chain reactions for carcinoembryonic antigen and cytokeratin 20 [J]. J Surg Oncol. 1998, 68(1): 34-40.
20. Patten LC, Berger DH, Rodriguez-Bigas M, et al. A prospective evaluation of radiocolloid and immunohistochemical staining in colon carcinoma lymphatic mapping [J]. Cancer, 2004, 100(10): 2104-2109.
21. Gu J, Zhao J, Li Z, et al. Clinical application of radioimmunoguided surgery in colorectal cancer using 125I-labeled carcino embryonic antigen-specific monoclonal antibody submucosally [J]. Dis Colon Rectum, 2003, 46(12): 1659-1666.
22. Saha S, Bilchik A, Wiese D, et al. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique-a multicenter trial [J]. Ann Surg Oncol, 2001, 8(9 Suppl): 94S-98S.
23. Verrill C, Carr NJ, Wilkinson-Smith E, et al. Histopathological assessment of lymph nodes in colorectal carcinoma: does triple levelling detect significantly more metastases [J]? J Clin Pathol, 2004, 57(11): 1165-1167.
24. Bosch B, Guller U, Schnider A, et al. Perioperative detection of disseminated tumour cells is an independent prognostic factor in patients with colorectal cancer [J]. Br J Surg, 2003, 90(7):882-888.
25. Kanellos I, Demetriades H, Zintzaras E, et al. Incidence and prognostic value ofpositive peritonea! cytology in colorectal cancer [J]. Dis Colon Rectum, 2003 , 46(4): 535-539.
26. Zhang XW, Yang HY, Fan P, et al. Detection of micrometastasis in peripheral blood by multi-sampling in patients with colorectal cancer [J]. World J Gastroenterol, 2005, 11(3): 43643-43648.
27. Linnemann U, Schimanski CC, Gebhardt C, et al. Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up exanunations [J]. Int J Colorectal Dis, 2004, 19(4): 380-386.
28.李世拥,骆成玉,安萍,等.大肠癌患者门静脉血p53和k-ras基因突变的检测及临床意义[J].中华外科杂志, 2001, 39(6): 440-441.
29. Itabashi T, Maesawa C, Uchiyama M, et al. Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes [J]. Int J Oncol, 2004, 24(3): 687-696.
30. Di Giacomo M, Altomare D, Guanti G. Micrometastasis in colorectal cancer [J]. Acta Chir Iugosl, 2002, 49(2): 63-66.
31. Vlems FA, Diepstra JH, Cornelissen IM, et al. Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection [J]. Anticancer Res, 2003, 23(lA): 179-186.
32. Conzelmann M, Linnemann U, Berger R, Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use [J]? Int J Colorectal Dis, 2005, 20(2): 137-146.
33. Chen XM, Chen GY, Wang ZR, et al. Detection of micrometastasis of gastric carcinoma in peripheral blood circulation [J]. World J Gastroenterol, 2004, 10(12): 804-808.
34. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction [J]. Lancet JT, 1991, 338(8777), 1227-1229.
35. Oberg AN, Lindmark GE, Israelsson AC, et al. Detection of occult tumour cells in lymph nodes of colorectal cancer patients using realtime quantitative RT-PCR for CEA and CK20 mRNAs [J]. Int J Cancer, 2004, 111(6): 101-110.
36.施林祥,李东辉.实时荧光PCR研究新进展[J].世界华人消化杂志, 2005, 13(10): 596-599.
37. Weitz J, Koch M, Debus J, et al. Colorectal cancer [J]. Lancet, 2005, 365(9454): 153-165.
38. Di Giacomo M, Altomare D, Guanti G. Micrometastasis in colorectal cancer [J]. Acta Chir Iugosl, 2002, 49(2): 63-66.
39. Noura S, Yamamoto H, Ohnishi T, et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry [J]. J Clin Oncol, 2002, 20(20): 4232-4241.
40. Takayama O, Yamamoto H, Ikeda K, et al. Application of RT-PCR to clinical diagnosis of micrometastasis of colorectal cancer: A translational research study [J]. Int J Oncol, 2004, 25(3): 597-604.
41. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review [J]. J Surg Oncol, 1998, 67(21): 194-202.
42. Chen WS, Chung MY, Liu JH, et al. Impact of Circulating Free Tumor Cells in the Peripheral Blood of Colorectal Cancer Patients during Laparoscopic Surgery [J]. World J Surg, 2004, 28(6): 552-557.
43. Palma RT, Waisberg J, Bromberg SH, et al. Micrometastasis in regional lymph nodes of extirpated colorectal carcinoma: immunohistochemical study using anti-cytokeratin antibodies AE1/AE3 [J]. Colorectal Dis, 2003, 5(2): 164-168.
44. Compton CC. Surgical pathology for the oncology patient in the age of standardization of margins, micrometastasis, and molecular markers [J]. Semin Radiat Oncol, 2003, 13(4): 382-388.
45. Noura S, Yamamoto H, Miyake Y, et al. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer [J]. Clin Cancer Res, 2002, 8(3): 759-767.
46. Waldman SA, Cagir B, Rakinic J, et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer [J]. Dis Colon Rectum, 1998, 41(3): 310-315.
1. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth [J]. Cancer Res, 1996, 56(4): 921-924.
2. Tortola S, Marcuello E, Gonzalez I, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer [J]. J Clin Oncol, 1999, 17(5): 1375-1381.
3. Mosnier JF, Perret AG, Vindimian M, et al. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum [J]. Arch Pathol Lab Med, 1996, 120(7): 654-659.
4. Liu Y. The human hepatocyte growth factor receptor gene: Complete strucural organization and promoter characterization [J]. Gene, 1998, 215(1): 159-169.
5. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for the rapeutic inhibition [J]. Cancer Metastasis Rev, 2003, 22(4): 309-325.
6. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene, 1992, 7(1): 181-185.
7. Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases [J]. Clin Cancer Res, 2003, 9(4): 1480-1488.
8. Kern A, Taubert H, Scheele J, et al. Association of p53 mutations, micro vessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases [J]. Int J Oncol, 2002, 21(2): 243-249.
9. Tachibana M, Kawamata H, Fujimori T, et al. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14AFR, p33ING1, p21WAF1 and MDM2 [J]. Int J Oncol, 2004, 25(4): 913-920.
10.沈仲毅,沈天伟,陆佩华,等. CD44基因拼接, p53基因突变和染色体倍性与大肠癌转移之间关系的机理研究[J].中国免疫学杂志, 2000, 16(1): 29-30.
11. Goi T, Yamaguchi A, Nakagawara G, et al. Reduced expression of deleted colorectal caocinoma(DCC) protein in established colon cancers[J]. Br J Cancer, 1998, 77(3): 466-471.
12. Zhang H, Arbman G, Sun XF. Codon 201 polymorphism of DCC gene is aprognostic factor in patients with colorectal cancer [J]. Cancer Detect Prev, 2003, 27(3): 216-221.
13. Wang L, Patel U, Ghosh L, et al. Mutation in the nm23 gene is associated with metastasis in colorectal cancer [J]. Cancer Res, 1993, 53(4): 717~720.
14.徐永建,刘歆农,刘庆宏,等.大肠癌nm23H-l基因表达及其临床意义[J].中国肿瘤临床, 2001, 28(12): 892-894.
15. Yamaguchi A, Urano T, Fushida S, et al. Inverse association of nm23- Hlexpression by colorectal cancer with liver metastasis [J]. Br J Cancer, 1993, 68(5): 1020-1025.
16. Shin KH, Park YJ, Park JG. PTEN gene mutations in colorectal cancers displaying microsatellite instability [J]. Cancer Lett, 2001, 174(2): 189-194.
17. Zhou XP, Kuismanen S, Nystrom Lahti M, et al. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors [J]. Hun Mol Genet, 2002, 11(4): 445-450.
18. Dicuonzo G, Angeletti S, Garcia Foncillas J, et al. Colorectal carcinomas and PTEN/MMAC1 gene mutations [J]. Clin Cancer Res, 2001, 7(12): 4049-4053.
19.辛彦,赵风凯,张素敏,等. CD44v6基因编码蛋白表达与胃癌转移和预后的关系[J].世界华人消化杂志, 1999, 7(3): 210-214.
20. Liu YJ, Yan PS, Li J, et al. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer [J]. World J Gastroenterol, 2005, 11(42): 6601-6606.
21. Heider KH, Offerhaus GJA, et al. Experssion of CD44 variant proteins in human colorectal cancer is related to tumor progression [J]. Cancer Res, 1993, 53(20): 4754-4756.
22.顾晋,祝学光,叶颖江,等.粘附分子的表达与大肠癌转移相关的分析[J].中华外科杂志, 1999, 37(2): 109-112.
23. Tachimori A, Yamada N, Sakate Y, et al. Up regulation of ICAM-1 gene expression inhibits tumor growth liver metastasis in colorectal carcinoma [J]. EurJCancer, 2005, 41(12): 1802-1810.
24. Kang X, Wang F, Xie JD, et al. Clinical evaluation of serum concentrtions of intercellular adhesion molecule-1in patients with colorect cancer [J]. World J Gastroenterol, 2005, 11(27): 4250-4253.
25. Joo M, LeeHK, KangYK. Expression of E-cadherin beta-catenin, CD44s andCD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis [J]. Anticancer Res, 2003, 23(2): 1581-1588.
26. Shiozaki H, Oka H, Inoue M, et a1. E-cadherin mediated adhesion system in cancer cells [J]. Cancer, 1996, 77(8): 1605-1613.
27. Bornman DM, Mathew S, Alsruhe J, et al. Methylation of the E-cadherin gene bladder neoplasia and in normal urothelial epithelium from elderly individuals [J]. Am J Pathol, 2001, 159(3): 831-835.
28. Elzagheid A, Algars A, Bendardaf R, et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome [J]. World J Gastroenterol, 2006, 12(27): 4304-4309.
29. De-Melker AA, Sonnenberg A. Integrins: alteralive splicing as a mechanism to regulate ligand binding and integrin signaling events [J].Bioessays, 1999, 21(6): 499-509.
30. ZhoU J, Ding YQ, Yang HJ, et al. Correlation between integrin alpha5beta1 expression in colorectal carcinomas and the biological bohavior of the carcinoma cells [J]. Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(8): 806-808.
31. Peeters CF, RuersTJ, Westphal JR, et al. Progressive loss of endothelial P-selectin expression with increasing malignancy in colorectal cancer [J]. Lab Invest, 2005, 85(2): 248-256.
32. Uner A, Akcali Z, Unsal D. Serum levels of soluble E-selectin in colorectal cancer [J]. Neoplasma, 2004, 51(4): 269-274.
33. Nemoto T, Kubota S, Ishida H, et al. Ornithine decarboxylase, mitogenactivated protein kinase and matrix metalloproteinase-2 expressions in human colon tumors [J]. World J Gastroenterol, 2005, 11(20): 3065-3069
34. Li BH, Zhao P, Liu SZ, et al. Matrix metalloproteinase-2 and tissue inhibitor ofmetallo-proteinase-2 in colorectal carcinoma invasion and metastasis [J]. World J Gastroenterol, 2005, 11(20): 3046-3050.
35. Ghilardi G, Biondi ML, Erario M, et al. Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter Polymorphisms [J]. Clin Chem, 2003, 49(11): 1940-1942.
36. Wang WS, Chen PM, Wang HS, et al. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma [J]. Carcinogenesis, 2006, 27(5): 1113-1120.
37. Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin B and MMP-9gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis [J]. Oncogene, 2004, 23(27): 4681-4689.
38. Ellis LM, Staley CA, Liu W, et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src [J]. J Bio Chem, 1998, 273(2): 1052-1057.
39. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and VEGF expression as prognostic factors in nodenegative colon cancer [J]. Arch Surg, 1997, 132(5): 541-546.
40.孟冬娅,薛文成,胡晓,等.血管内皮生长因子的大肠癌诊治中的应用研究[J].实用癌症杂志, 2001, 16(1): 46-48.
41. Kraft A, Weindel K, Ochs Atitel, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmali gnant disease [J]. Cancer, 1999, 85(1): 178.
42. Kumr H, Heerk, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer [J]. Clin Cancer Res, 1998, 4(5): 1279.
43. Clarijs R, Schalkwijk L, Hofmann UB, et al. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma [J]. Cancer Res, 2002, 62(23): 7059-7065.
44. Kriehuber E, Breiteneder-Geleff S, Groeger M, et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages [J]. J Exp Med, 2001, 194(6): 797-808.
45. Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis [J]. Cancer Res, 2001, 61(22): 8079-8084.
46. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype [J]. EMBO J, 2002, 21(7): 1505-1513.
2. Osaka H, Yashiro M, Sawada T, et al. Is a lymph node detected by the dye-guided method a true sentinel node in gastric cancer [J]? Clin Cancer Res, 2004, 10(20): 6912-6918.
3.黄洁夫主编.腹部外科学[M],第一版.北京:人民卫生出版社, 2001, 1025-1030.
4. Hohmann HP, Remy R, Brockhaus M, et al. Two different cell types have different major receptors for humam tumor necrosis factor (TNF) [J]. J Biol Chem, 1989, 264 (25): 14927-14934.
5. Schultz RM, Altom MG. Protective activity of recombinant murine tumor necrosis factor-alpha and interferon-gamma against experimental murine lung carcinoma metastases [J]. J Interferon Res, 1990, 10(2): 229-236.
6. Paul NL, Ruddle NH. Lymph toxin. Annu Rev Immunol, 1988, 6(3): 407-438.
7.巴德年主编.当代免疫学技术与应用[M],第一版.北京:北京医科大学,中国协和医科大学出版联社, 1998, 52-54.
8. Van OX, Vandenabeele P, Everaerdt B, et al. Human TNF mutants with selective activity on the p55 receptor [J]. Nature, 1993, 361(6409): 266-299.
9. Janicke R, Mannel DN. Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis [J]. J Immunol, 1990, 144(3): 1144- 1149.
10. Occleston NL, Walker C. Production of multiple growth factors by a human non-small cell lung carcinoma cell line [J]. Cancer Lett, 1993, 71 (1-3): 203-210.
11.刘宇,贾友鹏,巩鹏,等.胆管癌中肿瘤坏死因子α及肿瘤坏死因子受体Ⅰ表达情况的研究[J].中国医师进修杂志, 2006, 29 (5): 33-36.
12. Volland S, Amtmann E, Sauer G. TNF accelerates the S-phase of the cell cycle in tumor cells [J]. Int J Cancer, 1994, 56(5): 698-705.
13. Utaisincharoen P, Ubol S, Tangthawornchaikul N, et al. Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RⅠinduces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines [J]. Clin Exp Immunol, 1999, 116(1): 41-47.
14. Chinnaiyan AM, Dixit VM. Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis [J]. Semin Immunol, 1997, 9(1): 69-76.
15. Chambers WM, Khan U, Gagliano A, et al. Tumour morphology as a predictor of outcome after local excision of rectal cancer [J]. Br J Surg, 2004, 91(4): 457-459.
16. Tominaga K, Nakanishi Y, Nimura S, et al. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma [J]. Dis Colon Rectum, 2005, 48(1): 92-100.
17. Yamamoto S, Watanabe M, Hasegawa H, et a1. The risk of lymph node metastasis in T1 colorectal carcinoma [J]. Hepatogastroenterology. 2004, 51(58): 998-1000.
18. Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study [J]. J Gastroenterol. 2004, 39(6): 534-543.
19. Moll R, Zimbelmann R, Goldschmidt MD, et al. The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas [J] . Differentiation , 1993 , 53(2): 75-93.
20.朱正,刘青,赵勇,等.恶性上皮性肿瘤中CK20的表达及其临床意义[J].临床与实验病理学杂志, 2004, 20(3): 332.
21. Funaki NO, Tanaka J, Itami A, et al. Detection of colorectal carcinoma cells in circulating peripheral blood by reverse transcription-polymerase chain reaction targeting cytokeratin-20 Mrna [J]. Life Sci, 1997, 60(9): 634-652.
1.黄洁夫主编.腹部外科学[M],第一版.北京:人民卫生出版社, 2001, 1025-1030.
2. Ovaska J, Jarvinen H, Kujari H, et al. Follow-up of patients operated on for colorectal carcinoma [J]. Am J Surg, 1990, 159(6): 593-596.
3. Kune GA, Kune S, Field B, et al. Survival in patients with large-bowel cancer [J]. Dis Colon Rectum, 1990, 33(11): 938-946.
4. Dean GT, Parks TG, Rowlands BJ, et al. Prognostic factors in colorectal cancer [J]. Lancet, 1995, 345(8960): 1257-1259.
5. Feezor RJ, Copeland EM, Hochwald SN, et al. Significance of micrometastases in colorectal cancer[J]. Ann Surg Oncol, 2002, 9(10): 944-953.
6. Hayashi N, Arakawa H, Nagase H, et al. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method [J]. cancer Res, 1994, 54(14): 3853-3856.
7. Hermanek P, Hutter RV, Sobin LH, et al. International union against cancer. Classification of isolated tumor cells and micrometastasis [J]. Cancer, 1999, 86(12): 2668-2673.
8. Ross GL, Shoaib T, Soutar DS, et al. The first international conference sentinel node biopsyin mucosal head and neck cancer and adoption of a multicenter trialprotocol [J]. Ann Surg Oncol, 2002, 9(4): 406-410.
9. Sedmak DD, Meineke TA, Knechtges DS. Detection of metastatic breast carcinoma with monoclonal antibodies to cytokeratins [J]. Arch Pathol Lab Med, 1989, 113(7): 786-789.
10. Leong AS. The prognostic dilemma of nodal micrometastases in breast carcinoma [J]. Gan To Kagaku Ryoho, 2000, 27(2): 315-320.
11. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review[J]. J Surg Oncol, 1998, 67(3): 194-202.
12. Davidson BR, Sams VR, Styles J, et al. Detection of occult nodal metastases in patients with colorectal carcinoma [J]. Cancer, 1990, 65(4): 967-970.
13. Mori M, Mimori K, Inoue H, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase reaction [J]. Cancer Res, 1995, 55(15): 3417-3420.
14. Gerhard M, Juhl H, Kalthoff H, et al. Specific detection of carcinoembryonicantigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction [J]. J Clin Oncol, 1994, 12(4): 725-729.
15. Moll R, Lowe A, Franke WW. Cytokeratin 20 in human carcinomas: a new histodiagnostic marker detected by monoclonal antibodies [J]. AM J Pathol, 1992, 140(2): 427-447.
16. Dorudi S, Kinrade E, Marshall NC, et al. Genetic detection of lymph node micrometastases in patients with colorectal cancer [J]. Br J Surg, 1998, 85(1): 98-100.
17.朱正,刘青,赵勇,等.恶性上皮性肿瘤中CK20的表达及其临床意义[J].临床与实验病理学杂志, 2004, 20(3): 332.
18. Moll I, Kuhn C, Moll R. Cytokeratin 20 is a general marker of cutaneous Merkel cells while certain neuronal proteins are absent [J]. J Invest Dermatol, 1995, 104(6): 910-915.
19.刘宇,贾友鹏,巩鹏,等.胆管癌中肿瘤坏死因子α及肿瘤坏死因子受体Ⅰ表达情况的研究[J].中国医师进修杂志, 2006, 29(5): 33-36.
20. Volland S, Amtmann E, Sauer G. TNF accelerates the S-phase of the cell cycle in tumor cells [J]. Int J Cancer, 1994, 56(5): 698-705.
21. Denis MG, Lipart C, Leborgne J, et al. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients [J]. Int J Cancer, 1997, 74(5): 540-544.
22. Noura S, Yamamoto H, Ohnishi T, et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry [J]. J Clin Oncol, 2002, 20(20): 4232-4241.
23. Takayama O, Yamamoto H, Ikeda K, et al. Application of RT-PCR to clinical diagnosis of micrometastasis of colorectal cancer: A translational research study [J]. Int J Oncol, 2004, 25(3): 597-604.
1. Somlyo AV, Bradshaw D, Ramos S,et al. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells [J].Biochem Biophys Res Common, 2000, 269(3): 652-659.
2. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth [J]. Cancer Res, 1996, 56(4): 921-924.
3. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis [J]. Cancer Chemother Pharmacol, 1999, 43 Suppl: S42-51.
4. Debruyne P, Vermeulen S, Mareel M. The role of the E-cadherin/catenin complex in gastrointestinal cancer [J]. Acta Gastroenterol Belg, 1999, 64(4): 393-402.
5. Patel AS, Schechter GL, Wasilenko WJ, et al. Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro [J]. Oncogene, 1998, 16(25): 3227-3332.
6. Tachado SD, Mayhew MW, Wescott GG, et al. Regulation of tumor invasion and metastasis in protein kinase C epsilon-transformed NIH3T3 fibroblasts [J]. J Cell Biochem, 2002, 85(4): 785-797.
7. Tullberg K, Haidvogl H, Obrist R, et al. Selection of highly malignant tumour cells using reconstituted basement membrane matrix [J]. Invasion Metastasis, 1989, 9(1): 15-26.
8.杨子昂,靳大勇,吴国象,等.基质金属蛋白酶及其抑制因子检测结直肠癌术后肝转移的研究[J].中国实用外科杂志, 2004, 24(3): 171-172.
9.吴莉,姜彬,杨洁,等.参芪扶正注射液联合化疗治疗晚期非小细胞肺癌30例[J].中国中西医结合杂志, 2004, 24(6): 567-568.
10.耿维风,陈敏.参芪扶正注射液临床初步观察[J].中国医院药学杂志, 2003, 23(9): 554-556.
11.王晓华,郑颖.现代简明中医中药[M].南京:江苏科技出版社, 2005, 281-284.
12.姚志华,张明智.中药抗恶性肿瘤研究进展[J].现代肿瘤医学, 2006, 14(4): 503-505.
13.付玉兰,李辉贤,雷成阳,等.参芪扶正注射液配合卵巢癌术后化疗临床观察[J].现代肿瘤医学, 2005, 13(1): 110-111.
14. Fridkis-Hareli M, Reinherz EL. New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination[J].Med Immuno, 2004, 3(1): 2.
15. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity [J]. Nat Rev Microbiol, 2005, 3(1): 59-69.
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 [J]. CA Cancer J Clin, 2007, 57(1): 43-66.
2.吴阶平,裘法祖主编.黄家驷外科学[M],第六版.北京:人民卫生出版社, 1999,1134-1135.
3.黄洁夫主编.腹部外科学[M],第一版.北京:人民卫生出版社, 2001, 1025-1030.
4. Wheeler JM, Dodds E, Warren BF, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade [J]. Dis Colon Rectum, 2004, 47(12): 2025-2031.
5. Papadopoulou-Zekeridou P, Alexandridis E, Delithanasis I, et al. Adjuvant chemotherapy in colorectal cancer [J]. Tech Coloproctol, 2004, 8 Suppl 1: 149-151.
6.汤钊猷主编.现代肿瘤学[M],第二版.上海:上海医科大学出版社, 2002, 521-552.
7. Spiliotis J, Datsis A. The surgical approach to locally recurrent rectal cancer [J]. Tech Coloproctol, 2004, 8 Suppl 1: s33-35.
8. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review [J]. J Surg Oncol, 1998, 67(3): 194-202.
9.朱世能,陆世伦主编.肿瘤基础理论[M],第二版.上海:上海医科大学出版社, 2000, 264-279.
10. Chambers WM, Khan U, Gagliano A, et al. Tumour morphology as a predictor of outcome after local excision of rectal cancer [J]. Br J Surg, 2004, 4(2): 457-459.
11. Tominaga K, Nakanishi Y, Nimura S, et al. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma [J]. Dis Colon Rectum, 2005 , 48(1): 92-100.
12. Yamamoto S, Watanabe M, Hasegawa H, et a1.The risk of lymph node metastasis in T1 colorectal carcinoma [J]. Hepatogastroenterology, 2004, 51(58): 998-1000.
13. Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study [J]. J Gastroenterol, 2004, 39(6): 534-543.
14. Scheidbach H, Lippert H, Kockerling F. Laparoscopic colorectal resection with curative intent. Own results and review of the literature [J]. Minerva Chir, 2003, 58(4): 439-446.
15. Shirouzu K, Ogata Y, Araki Y. Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer [J]. Dis Colon Rectum, 2004, 47(9): 1442-1447.
16. Ueno H, Hase K, Mochizuki H. Criteria for extramural perineural invasion as a prognostic factor in rectal cancer [J]. Br J Surg, 2001, 88(7): 994-1000.
17.龚丽明,程若川,李恩全.大肠癌微转移检测的现状及展望[J].大肠肛门病外科杂志, 2003, 9(3): 137-142.
18. Braat AE, Oosterhuis JW, Moll FC, et al. Successful sentinel node identification in colon carcinoma using Patent Blue V [J]. Eur J Surg Oncol, 2004, 30(6): 633-637.
19. Futamura M, Takagi Y, Koumura H, et al. Spread of colorectal cancer micrometastasis in reginal lymph node by reverse transcriptase polymerise chain reactions for carcinoembryonic antigen and cytokeratin 20 [J]. J Surg Oncol. 1998, 68(1): 34-40.
20. Patten LC, Berger DH, Rodriguez-Bigas M, et al. A prospective evaluation of radiocolloid and immunohistochemical staining in colon carcinoma lymphatic mapping [J]. Cancer, 2004, 100(10): 2104-2109.
21. Gu J, Zhao J, Li Z, et al. Clinical application of radioimmunoguided surgery in colorectal cancer using 125I-labeled carcino embryonic antigen-specific monoclonal antibody submucosally [J]. Dis Colon Rectum, 2003, 46(12): 1659-1666.
22. Saha S, Bilchik A, Wiese D, et al. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique-a multicenter trial [J]. Ann Surg Oncol, 2001, 8(9 Suppl): 94S-98S.
23. Verrill C, Carr NJ, Wilkinson-Smith E, et al. Histopathological assessment of lymph nodes in colorectal carcinoma: does triple levelling detect significantly more metastases [J]? J Clin Pathol, 2004, 57(11): 1165-1167.
24. Bosch B, Guller U, Schnider A, et al. Perioperative detection of disseminated tumour cells is an independent prognostic factor in patients with colorectal cancer [J]. Br J Surg, 2003, 90(7):882-888.
25. Kanellos I, Demetriades H, Zintzaras E, et al. Incidence and prognostic value ofpositive peritonea! cytology in colorectal cancer [J]. Dis Colon Rectum, 2003 , 46(4): 535-539.
26. Zhang XW, Yang HY, Fan P, et al. Detection of micrometastasis in peripheral blood by multi-sampling in patients with colorectal cancer [J]. World J Gastroenterol, 2005, 11(3): 43643-43648.
27. Linnemann U, Schimanski CC, Gebhardt C, et al. Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up exanunations [J]. Int J Colorectal Dis, 2004, 19(4): 380-386.
28.李世拥,骆成玉,安萍,等.大肠癌患者门静脉血p53和k-ras基因突变的检测及临床意义[J].中华外科杂志, 2001, 39(6): 440-441.
29. Itabashi T, Maesawa C, Uchiyama M, et al. Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes [J]. Int J Oncol, 2004, 24(3): 687-696.
30. Di Giacomo M, Altomare D, Guanti G. Micrometastasis in colorectal cancer [J]. Acta Chir Iugosl, 2002, 49(2): 63-66.
31. Vlems FA, Diepstra JH, Cornelissen IM, et al. Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection [J]. Anticancer Res, 2003, 23(lA): 179-186.
32. Conzelmann M, Linnemann U, Berger R, Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use [J]? Int J Colorectal Dis, 2005, 20(2): 137-146.
33. Chen XM, Chen GY, Wang ZR, et al. Detection of micrometastasis of gastric carcinoma in peripheral blood circulation [J]. World J Gastroenterol, 2004, 10(12): 804-808.
34. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction [J]. Lancet JT, 1991, 338(8777), 1227-1229.
35. Oberg AN, Lindmark GE, Israelsson AC, et al. Detection of occult tumour cells in lymph nodes of colorectal cancer patients using realtime quantitative RT-PCR for CEA and CK20 mRNAs [J]. Int J Cancer, 2004, 111(6): 101-110.
36.施林祥,李东辉.实时荧光PCR研究新进展[J].世界华人消化杂志, 2005, 13(10): 596-599.
37. Weitz J, Koch M, Debus J, et al. Colorectal cancer [J]. Lancet, 2005, 365(9454): 153-165.
38. Di Giacomo M, Altomare D, Guanti G. Micrometastasis in colorectal cancer [J]. Acta Chir Iugosl, 2002, 49(2): 63-66.
39. Noura S, Yamamoto H, Ohnishi T, et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry [J]. J Clin Oncol, 2002, 20(20): 4232-4241.
40. Takayama O, Yamamoto H, Ikeda K, et al. Application of RT-PCR to clinical diagnosis of micrometastasis of colorectal cancer: A translational research study [J]. Int J Oncol, 2004, 25(3): 597-604.
41. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review [J]. J Surg Oncol, 1998, 67(21): 194-202.
42. Chen WS, Chung MY, Liu JH, et al. Impact of Circulating Free Tumor Cells in the Peripheral Blood of Colorectal Cancer Patients during Laparoscopic Surgery [J]. World J Surg, 2004, 28(6): 552-557.
43. Palma RT, Waisberg J, Bromberg SH, et al. Micrometastasis in regional lymph nodes of extirpated colorectal carcinoma: immunohistochemical study using anti-cytokeratin antibodies AE1/AE3 [J]. Colorectal Dis, 2003, 5(2): 164-168.
44. Compton CC. Surgical pathology for the oncology patient in the age of standardization of margins, micrometastasis, and molecular markers [J]. Semin Radiat Oncol, 2003, 13(4): 382-388.
45. Noura S, Yamamoto H, Miyake Y, et al. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer [J]. Clin Cancer Res, 2002, 8(3): 759-767.
46. Waldman SA, Cagir B, Rakinic J, et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer [J]. Dis Colon Rectum, 1998, 41(3): 310-315.
1. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth [J]. Cancer Res, 1996, 56(4): 921-924.
2. Tortola S, Marcuello E, Gonzalez I, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer [J]. J Clin Oncol, 1999, 17(5): 1375-1381.
3. Mosnier JF, Perret AG, Vindimian M, et al. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum [J]. Arch Pathol Lab Med, 1996, 120(7): 654-659.
4. Liu Y. The human hepatocyte growth factor receptor gene: Complete strucural organization and promoter characterization [J]. Gene, 1998, 215(1): 159-169.
5. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for the rapeutic inhibition [J]. Cancer Metastasis Rev, 2003, 22(4): 309-325.
6. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene, 1992, 7(1): 181-185.
7. Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases [J]. Clin Cancer Res, 2003, 9(4): 1480-1488.
8. Kern A, Taubert H, Scheele J, et al. Association of p53 mutations, micro vessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases [J]. Int J Oncol, 2002, 21(2): 243-249.
9. Tachibana M, Kawamata H, Fujimori T, et al. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14AFR, p33ING1, p21WAF1 and MDM2 [J]. Int J Oncol, 2004, 25(4): 913-920.
10.沈仲毅,沈天伟,陆佩华,等. CD44基因拼接, p53基因突变和染色体倍性与大肠癌转移之间关系的机理研究[J].中国免疫学杂志, 2000, 16(1): 29-30.
11. Goi T, Yamaguchi A, Nakagawara G, et al. Reduced expression of deleted colorectal caocinoma(DCC) protein in established colon cancers[J]. Br J Cancer, 1998, 77(3): 466-471.
12. Zhang H, Arbman G, Sun XF. Codon 201 polymorphism of DCC gene is aprognostic factor in patients with colorectal cancer [J]. Cancer Detect Prev, 2003, 27(3): 216-221.
13. Wang L, Patel U, Ghosh L, et al. Mutation in the nm23 gene is associated with metastasis in colorectal cancer [J]. Cancer Res, 1993, 53(4): 717~720.
14.徐永建,刘歆农,刘庆宏,等.大肠癌nm23H-l基因表达及其临床意义[J].中国肿瘤临床, 2001, 28(12): 892-894.
15. Yamaguchi A, Urano T, Fushida S, et al. Inverse association of nm23- Hlexpression by colorectal cancer with liver metastasis [J]. Br J Cancer, 1993, 68(5): 1020-1025.
16. Shin KH, Park YJ, Park JG. PTEN gene mutations in colorectal cancers displaying microsatellite instability [J]. Cancer Lett, 2001, 174(2): 189-194.
17. Zhou XP, Kuismanen S, Nystrom Lahti M, et al. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors [J]. Hun Mol Genet, 2002, 11(4): 445-450.
18. Dicuonzo G, Angeletti S, Garcia Foncillas J, et al. Colorectal carcinomas and PTEN/MMAC1 gene mutations [J]. Clin Cancer Res, 2001, 7(12): 4049-4053.
19.辛彦,赵风凯,张素敏,等. CD44v6基因编码蛋白表达与胃癌转移和预后的关系[J].世界华人消化杂志, 1999, 7(3): 210-214.
20. Liu YJ, Yan PS, Li J, et al. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer [J]. World J Gastroenterol, 2005, 11(42): 6601-6606.
21. Heider KH, Offerhaus GJA, et al. Experssion of CD44 variant proteins in human colorectal cancer is related to tumor progression [J]. Cancer Res, 1993, 53(20): 4754-4756.
22.顾晋,祝学光,叶颖江,等.粘附分子的表达与大肠癌转移相关的分析[J].中华外科杂志, 1999, 37(2): 109-112.
23. Tachimori A, Yamada N, Sakate Y, et al. Up regulation of ICAM-1 gene expression inhibits tumor growth liver metastasis in colorectal carcinoma [J]. EurJCancer, 2005, 41(12): 1802-1810.
24. Kang X, Wang F, Xie JD, et al. Clinical evaluation of serum concentrtions of intercellular adhesion molecule-1in patients with colorect cancer [J]. World J Gastroenterol, 2005, 11(27): 4250-4253.
25. Joo M, LeeHK, KangYK. Expression of E-cadherin beta-catenin, CD44s andCD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis [J]. Anticancer Res, 2003, 23(2): 1581-1588.
26. Shiozaki H, Oka H, Inoue M, et a1. E-cadherin mediated adhesion system in cancer cells [J]. Cancer, 1996, 77(8): 1605-1613.
27. Bornman DM, Mathew S, Alsruhe J, et al. Methylation of the E-cadherin gene bladder neoplasia and in normal urothelial epithelium from elderly individuals [J]. Am J Pathol, 2001, 159(3): 831-835.
28. Elzagheid A, Algars A, Bendardaf R, et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome [J]. World J Gastroenterol, 2006, 12(27): 4304-4309.
29. De-Melker AA, Sonnenberg A. Integrins: alteralive splicing as a mechanism to regulate ligand binding and integrin signaling events [J].Bioessays, 1999, 21(6): 499-509.
30. ZhoU J, Ding YQ, Yang HJ, et al. Correlation between integrin alpha5beta1 expression in colorectal carcinomas and the biological bohavior of the carcinoma cells [J]. Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(8): 806-808.
31. Peeters CF, RuersTJ, Westphal JR, et al. Progressive loss of endothelial P-selectin expression with increasing malignancy in colorectal cancer [J]. Lab Invest, 2005, 85(2): 248-256.
32. Uner A, Akcali Z, Unsal D. Serum levels of soluble E-selectin in colorectal cancer [J]. Neoplasma, 2004, 51(4): 269-274.
33. Nemoto T, Kubota S, Ishida H, et al. Ornithine decarboxylase, mitogenactivated protein kinase and matrix metalloproteinase-2 expressions in human colon tumors [J]. World J Gastroenterol, 2005, 11(20): 3065-3069
34. Li BH, Zhao P, Liu SZ, et al. Matrix metalloproteinase-2 and tissue inhibitor ofmetallo-proteinase-2 in colorectal carcinoma invasion and metastasis [J]. World J Gastroenterol, 2005, 11(20): 3046-3050.
35. Ghilardi G, Biondi ML, Erario M, et al. Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter Polymorphisms [J]. Clin Chem, 2003, 49(11): 1940-1942.
36. Wang WS, Chen PM, Wang HS, et al. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma [J]. Carcinogenesis, 2006, 27(5): 1113-1120.
37. Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin B and MMP-9gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis [J]. Oncogene, 2004, 23(27): 4681-4689.
38. Ellis LM, Staley CA, Liu W, et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src [J]. J Bio Chem, 1998, 273(2): 1052-1057.
39. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and VEGF expression as prognostic factors in nodenegative colon cancer [J]. Arch Surg, 1997, 132(5): 541-546.
40.孟冬娅,薛文成,胡晓,等.血管内皮生长因子的大肠癌诊治中的应用研究[J].实用癌症杂志, 2001, 16(1): 46-48.
41. Kraft A, Weindel K, Ochs Atitel, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmali gnant disease [J]. Cancer, 1999, 85(1): 178.
42. Kumr H, Heerk, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer [J]. Clin Cancer Res, 1998, 4(5): 1279.
43. Clarijs R, Schalkwijk L, Hofmann UB, et al. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma [J]. Cancer Res, 2002, 62(23): 7059-7065.
44. Kriehuber E, Breiteneder-Geleff S, Groeger M, et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages [J]. J Exp Med, 2001, 194(6): 797-808.
45. Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis [J]. Cancer Res, 2001, 61(22): 8079-8084.
46. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype [J]. EMBO J, 2002, 21(7): 1505-1513.